John Campbell, a physician known for his unfiltered takes on medical policy, delivers a provocative argument that two of the world's most accessible treatments—ivermectin and iodine—are being systematically denied to patients in the UK. He doesn't just question the efficacy of these substances; he frames their unavailability as a deliberate suppression of science by a "nanny state" more interested in protecting pharmaceutical profits than saving lives. For the busy professional who has heard the noise but missed the specifics, Campbell's on-the-ground reporting from Uganda and his personal medical experiments offer a stark, if controversial, counter-narrative to mainstream guidelines.
The Economics of Suppression
Campbell opens with a tangible demonstration of the ivermectin paradox: a Nobel Prize-winning drug that costs pennies yet remains off-limits for many conditions. He holds up a box of generic tablets from India, noting that a hundred pills cost only twenty dollars. "This is a drug that seems to be completely suppressed," he asserts, citing Pierre Cory's book The War on Ivermectin to bolster his claim of a coordinated effort to bury the treatment. His reasoning is economic rather than clinical: because the drug is generic, no massive profit can be made, and therefore, no large-scale randomized trials will ever be funded.
The author argues that this lack of funding creates a catch-22 where the drug cannot be proven effective because it is not tested, yet it cannot be tested because it is not profitable. "That's not going to happen because people can't make any money out of a generic drug," Campbell writes. He suggests a pragmatic alternative: allowing patients to use the drug on a "right to try" basis to generate real-world data. "If thousands of people tried it, tens of thousands of people tried it, then very soon there you've got your cohorts," he explains, proposing that matched-pair analysis could replace the impossible gold standard of double-blind trials.
Critics might note that relying on uncontrolled, self-selected cohorts introduces massive bias and confounding variables, making it difficult to distinguish the drug's effects from the natural course of disease or the placebo effect. However, Campbell's frustration is palpable when he describes the current regulatory environment as a "complete travesty" that prevents science from following where the evidence leads.
"If you don't do this, politicians, I accuse you of curiosity deficit disorder, which is the anti-thesis of the way science works."
The Iodine Paradox
Shifting gears, Campbell turns his attention to iodine, a substance he describes as a "staple of medicine for hundreds of years" that is now effectively banned from UK pharmacy shelves. He recalls a time when mothers routinely applied iodine to children's scrapes, a practice he finds bafflingly obsolete in modern Britain. "You're not allowed to buy iodine over the counter in British chemists," he states, highlighting the absurdity of restricting the "world's most effective antiseptic."
He details his personal regimen, taking dilute Lugol's iodine for prostate health and recounting a specific instance where he took ivermectin daily for seven weeks to combat a high PSA reading. "I thought if I had prostate cancer, it might be effective," he admits, noting that while his PSA did not drop, the experience underscored the lack of data available to patients. He argues that the prohibition on iodine is not based on safety but on a paternalistic fear that the public cannot handle simple, cheap remedies. "Stupid people like you and me, we don't know how to use iodine properly," he mocks the regulatory logic, suggesting the ban is a way to keep people sick and dependent on expensive pharmaceuticals.
While Campbell's anecdotal evidence is compelling to his audience, the medical community would counter that iodine's safety profile varies wildly by concentration and that the risks of thyroid dysfunction from unsupervised use are significant. Yet, his core question remains a powerful rhetorical device: why is a centuries-old, broad-spectrum antimicrobial treated as a contraband substance in a modern healthcare system?
Bottom Line
John Campbell's most potent argument lies in his exposure of the economic incentives that drive medical policy, forcing readers to confront the possibility that "safe" and "cheap" are liabilities in a profit-driven system. His biggest vulnerability, however, is the leap from anecdotal success to policy prescription, ignoring the rigorous safety data required for widespread adoption. Readers should watch for how this tension between patient autonomy and regulatory caution evolves as the debate over off-label treatments intensifies.